From a clinical perspective, our findings emphasize the potential value of integrating hepatic steatosis assessment and fetuin-A measurement into routine cardiovascular risk stratification for patients with type 2 diabetes mellitus. This evidence concerns the gene AHSG and type 2 diabetes mellitus.